Osteopontin is a marker for cancer aggressiveness and patient survival
Authors:
Open Access
- 7 September 2010
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 103 (6) , 861-869
Abstract
Background: Methods: Results: Conclusions:Keywords
This publication has 16 references indexed in Scilit:
- Toward a molecular classification of cancerToxicology, 2010
- Prostate kallikrein markers in diagnosis, risk stratification and prognosisNature Reviews Urology, 2009
- Molecular mechanisms of metastasisCancer Letters, 2008
- A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experimentsBioinformatics, 2008
- A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of MetastasisCancer Research, 2007
- RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysisBioinformatics, 2006
- Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9Clinical Cancer Research, 2006
- Comparing effect sizes in follow-up studies: ROC Area, Cohen's d, and r.Law and Human Behavior, 2005
- An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.2005
- Differential Gene Expression of TGF-β Family Members and Osteopontin in Breast Tumor Tissue: Analysis by Real-Time Quantitative PCRBreast Cancer Research and Treatment, 2002